Abstract
We were intrigued by reports of the inhibition of phospholipase A2 (PLA2) by indomethacin. In order to increase the potency of the indomethacin system as an inhibitor of PLA2, it was decided to make more lipophilic analogs. Indeed, covalent attachment of a quinoline ring to the methoxy substituent of indomethacin affords WAY-122,220 which is almost an order of magnitude more potent than indomethacin in inhibiting human synovial fluid PLA2 (IC50=15 and 145 μM, respectively). TheN−p-chloro-benzyl analog of this compound, WAY-121,520, was an even more potent inhibitor of PLA2 (IC50=4 μM). Structural analyses and molecular modeling suggest that these compounds may inhibit PLA2 by mimicking arachidonic acid. WAY-121,520 is also a potent leukotriene biosynthesis inhibitor both in the rat PMN and mouse macrophage assays (IC50=10 and 4 nM, respectively), possibly acting via a 5-LO (5-lipoxygenase) translocation inhibition mechanism. The multiple actions of WAY-121,520 may contribute to its favorable anti-inflammatory profile.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. E. Garst,Phospholipase A 2 inhibitors. Curr. Opin. Thera. Patents2, 400–408 (1992).
A. F. Kreft, A. Failli, J. H. Musser, D. M. Kubrak, A. L. Banker, R. Steffan, C. A. Demerson, J. Nelson, U. Shah, W. Grey, L. A. Marshall, D. Holloway, R. Sturm, R. P. Carlson, J. Berkenkopf, D. Grimes, B. M. Weichman and J. Y. Chang,Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor—a general route to novel antiinflammatory and antiallergy drugs. Drugs Expl. Clin. Res.17, 381–387 (1991).
L. Kaplan, J. Weiss and P. Elsbach,Low concentrations of indomethacin inhibit phospholipase A 2 of rabbit polymorphonuclear leukocytes Proc. Natl. Acad. Sci. USA75, 2955–2958 (1978).
J. H. Musser, A. F. Kreft, A. Failli, C. Demerson, U. Shah and J. Nelson,Substituted indole-, indene-, pyranoindole-, and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA 2 and lipoxygenase. World Patent Application WO 91/06537, 1991.
L. A. Marshall, J. Bauer, M. L. Sung and J. Y. Chang,Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A 2. J. Rheumatol.18, 59–65 (1991).
K. B. Glaser, M. S. De Carvalho, R. S. Jacobs, M. R. Kernan and D. J. Faulkner,Manoalide: Structure-activity studies and definition of the pharmacophore for phospholipase A 2 inhibition. Mol. Pharmacol.36, 782–788 (1989).
S. Charleson, P. Prasit, S. Leger, J. W. Gillard, P. J. Vickers, J. A. Mancini, P. Charleson, J. Guay, A. W. Ford-Hutchinson and J. F. Evans,Characterization of a 5-lipoxygenase-activating protein binding assay: Correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol. Pharmacol.41, 873–879 (1992).
R. Raghupathi and R. Franson,Inhibition of phospholipase A 2 by cis unsaturated fatty acids: Evidence for the binding of fatty acid to enzyme. Biochem. Biophys. Acta.1126, 206–214 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kreft, A., Nelson, J., Musser, J. et al. Structure-activity relationships leading to WAY-121,520, a tris aryl-type, indomethacin-based, phospholipase A2 (PLA2)/leukotriene biosynthesis inhibitor. Agents and Actions 39 (Suppl 1), C33–C35 (1993). https://doi.org/10.1007/BF01972712
Issue Date:
DOI: https://doi.org/10.1007/BF01972712